Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?

Negri, Francesca; Porta, Camillo

Negri, Francesca; Porta, Camillo.

Afiliación

Negri F; Medical Oncology Unit, University Hospital of Parma, Parma.
Porta C; Department of Biomedical Sciences & Human Oncology, University of Bari 'Aldo Moro', and Division of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy.

Oncol Rev ; 15(2): 564, 2021 Sep 21.

Article en En | MEDLINE | ID: mdl-34667489